Compare Amgen, Inc. (AMGN) vs Enbridge Inc (ENB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Enbridge Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Enbridge Inc trades at $54.82 (market cap $118.96B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Enbridge Inc pays the higher dividend (5.14%). Which is the better fit depends on your goals.
| AMGN | ENB | |
|---|---|---|
Market Cap | $196.12B | $118.96B |
Sector | Health | Energy |
52-Week High | $388.16 | $58.04 |
52-Week Low | $271.18 | $44.55 |
Enterprise Value | $241.41B | $199.76B |
Dividend Yield | 2.77% | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Enbridge (ENB) trades at $54.66, up 0.13% on the day, with a neutral technical signal and mixed earnings history. The company reported strong revenue growth to $65.19B in 2025 and maintains a 10% net income margin. Recent news highlights its 5.1% dividend yield and AI-driven growth projects, while analyst consensus is evenly split between Buy and Hold ratings.
Outlook remains balanced with steady cash flow and dividend appeal offset by high debt levels and earnings volatility. Key opportunities include infrastructure expansion and high yield, while risks involve interest rate sensitivity and execution challenges in capital projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
